The combination of targeted SCD and sorafenib may have a synergistic effect on LIHC (8), and a recently developed organic small molecule, fluoxetine, inhibits the endoplasmic reticulum (ER) of SREBP-1 by binding to the SCAP-Golgi translocation complex, thereby strongly inhibiting SREBP-1 activation to suppress LIHC development (9). The gene discussed is SREBF1; the disease is Schnyder corneal dystrophy.